Top pharma companies by sales loss due to patent expirations until 2018 | Statista
Does Drug Patent Evergreening Prevent Generic Entry? – DrugPatentWatch - Make Better Decisions
Teva Pharmaceutical Stock: Gem Among Generic Pharma Companies (NYSE:TEVA) | Seeking Alpha
Global Generic Drugs Market Report 2022: Rapid Patent Expiry of Branded Drugs Creates Opportunities
Patent Docs: Top Drugs Losing Patent Exclusivity in 2021
High-Court-Sides-Teva-Patent
Time for a Turnaround at Teva Pharmaceuticals Industries Ltd? | The Motley Fool
Sandoz and Teva invalidate blockbuster apixaban patent and SPC - JUVE Patent
Patent expiry dates for biologicals: 2018 update - GaBI Journal
Branded Generics Market Size, Share & Trends Report, 2030
Patent expiry dates for biologicals: 2016 update - GaBI Journal
Drug Patent Expirations and the “Patent Cliff”
Expiry of biologics patents positive for pharma this year, says survey
Silver Spring-based United Therapeutics settles patent dispute over Remodulin generic with Teva Pharmaceuticals - Washington Business Journal
Blockbuster immunology drugs facing patent expiry and biosimilar competition - Pharmaceutical Technology
Several blockbuster patents to expire in 2023 - BioStock
The biggest drug patent losses for 2013 - GaBI Journal
Truvada patent expires, potentially opening 'new doors' for PrEP access
PATENT EXPIRY DATES 1/3 | New Drug Approvals
Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug - Bloomberg
Patent expiry dates for biologicals: 2016 update - GaBI Journal
Teva Pharma Plunges After Two U.S. Copaxone Patents Invalidated | Investor's Business Daily
Top Drugs Losing Patent Protection in 2022 | Generic Drugs Entry in 2022
Crowell & Moring Client Alert: NJ Federal Court Says Pharmaceutical Manufacturers Can Agree to Keep Generics Off The Market
Top 5 expired blockbuster drugs - Clinical Trials Arena
